drugset / Trial / NCT06054464

A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants

NCT06054464

Phase 1 Completed 28 enrolled PMV Pharmaceuticals, Inc
Non-randomizedSequentialOpen-labelOther

Summary

This study will assess the effect of a Proton Pump Inhibitor (PPI) (rabeprazole) on the pharmacokinetics (PK) of PC14586 and the effect of an H2-receptor antagonist (famotidine) on the PK of PC14586

Timeline

Start
2023-09-19
Primary completion
2023-11-03
Completion
2024-02-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Famotidine Other / unclassified Oral
Subject Rabeprazole Small molecule Oral
Subject rezatapopt Small molecule Oral

Indications

No indication recorded.